TARSライブシグナル | Getagraph.comで利益を最大化

売る 109437 min ago

@ $29.83

発行日: 14 2月 2024 @ 01:42

リターン: 7.61%

前回のシグナル: 2月 9 - 23:30

前回のシグナル: 買う

リターン: -3.38 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:39):

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions...

Stats
本日の出来高	181 156
平均出来高	714 895
時価総額	1.20B
EPS	$0 ( 2024-02-27 )
次の収益日	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.95
ATR14	$0.0370 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Mottiwala Aziz	Buy	12 938	Common Stock
2024-03-18	Mottiwala Aziz	Sell	4 766	Common Stock
2024-03-15	Mottiwala Aziz	Sell	8 148	Restricted Stock Units
2024-03-15	Mottiwala Aziz	Sell	4 790	Restricted Stock Units
2024-03-15	Wahl Bryan	Buy	12 038	Common Stock

INSIDER POWER
31.16
Last 100 transactions
Buy: 1 038 524 \| Sell: 656 594

ボリューム相関

長: 0.15 (neutral)

短: -0.96 (very strong negative)

Signal:(43.109) Neutral

Tarsus Pharmaceuticals, 相関

10 最も正の相関
SLDP	0.904
HOOK	0.897
USEG	0.893
RDHL	0.884
VIRX	0.875
SVFD	0.874
ONDS	0.869
XFOR	0.867
MARPS	0.864
PLXP	0.858

10 最も負の相関
ITMR	-0.864
AVEO	-0.862
EWEB	-0.854
HZNP	-0.851
OPNT	-0.844
MICT	-0.841
DVCR	-0.84
BNIXU	-0.834
OCCIP	-0.833
ACIW	-0.832

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Tarsus Pharmaceuticals, 相関 - 通貨/商品

-0.40
( neutral )

-0.33
( neutral )

0.00
( neutral )

-0.26
( neutral )

0.37
( neutral )

-0.24
( neutral )

Tarsus Pharmaceuticals, 財務諸表

Annual	2023
収益:	$17.45M
総利益:	$15.85M (90.87 %)
EPS:	$-4.62

FY	2023
収益:	$17.45M
総利益:	$15.85M (90.87 %)
EPS:	$-4.62

FY	2022
収益:	$25.82M
総利益:	$24.86M (96.30 %)
EPS:	$-2.52

FY	2021
収益:	$57.03M
総利益:	$57.03M (100.00 %)
EPS:	$-0.00200

Financial Reports:

No articles found.

Tarsus Pharmaceuticals,

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.